Combined treatment with ruxolitinib and MK-2206 inhibits the JAK2/STAT5 and PI3K/AKT pathways via apoptosis in MDA-MB-231 breast cancer cell line
Esin Güvenir Çelik, Onur Eroğlu
Topics & Concepts
RuxolitinibProtein kinase BPI3K/AKT/mTOR pathwayPTENCancer researchJanus kinase 2Signal transductionBiologyMedicineChemistryInternal medicineCell biologyMyelofibrosisBone marrowCytokine Signaling Pathways and InteractionsMyeloproliferative Neoplasms: Diagnosis and TreatmentPI3K/AKT/mTOR signaling in cancer